Efficacy and Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: A 52-Week Retrospective Study from Italy Emphasizing Head and Neck Areas - Quiz - MDSpire

Efficacy and Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: A 52-Week Retrospective Study from Italy Emphasizing Head and Neck Areas

  • By

  • Luigi Gargiulo

  • Luciano Ibba

  • Matteo Bianco

  • Sara Di Giulio

  • Mario Valenti

  • Gianluca Avallone

  • Martina Zussino

  • Paolo Calzari

  • Angelo Valerio Marzano

  • Antonio Costanzo

  • Silvia Mariel Ferrucci

  • Alessandra Narcisi

  • March 28, 2026

  • 0 min

Share

Original Source(s)

Efficacy and Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: A 52-Week Retrospective Study from Italy Emphasizing Head and Neck Areas

  • by Luigi Gargiulo, Luciano Ibba, Matteo Bianco, Sara Di Giulio, Mario Valenti, Gianluca Avallone, Martina Zussino, Paolo Calzari, Angelo Valerio Marzano, Antonio Costanzo, Silvia Mariel Ferrucci, Alessandra Narcisi

  • March 28, 2026

Related Content

Evaluating Itch in Atopic Dermatitis: Perspectives from UK Dermatologists Through a Cross-Sectional Survey and Narrative Review

Evaluation of Baricitinib Administration for Atopic Dermatitis Patients in Spain: Insights from the DAMA-S Retrospective Chart Analysis

AI Scribes: Efficiency for Whom?

Unresolved safety, privacy, and regulatory concerns may limit benefits of AI scribes for physicians and patients.